PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction

Asthma Clinical Trial

Official title:

ALTA - ALbuterol/Budesonide Treatment in Acute Airway Obstruction. A Randomized, Double-blind, 2-period, Cross-over Study Evaluating Efficacy and Safety of Repeated Doses of PT027 Compared to PT007 in Patients With Asthma and Acute Airway Obstruction Induced by Repeated Mannitol Challenges

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05555290
• Other study ID #: D6930C00017
• Status: Recruiting
• Phase: Phase 3
• Start date: September 28, 2022
• Est. completion date: November 5, 2024

Study information

• Verified date: June 2024
• Source: AstraZeneca
• Contact: AstraZeneca Clinical Study Information Center
• Phone: 1-877-240-9479
• Email: information.center[@]astrazeneca.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study evaluating efficacy and safety of repeated doses of PT027 compared to PT007 in patients with asthma and acute airway obstruction induced by repeated mannitol challenges

Description:

This is a multi-center, randomized, double-blind, 2-period, cross-over study evaluating efficacy and safety of repeated doses of PT027 (albuterol/budesonide pressurized metered dose inhaler (pMDI)) compared to PT007 (albuterol pMDI) in participants with asthma and acute airway obstruction induced by 2 mannitol challenges at least 8 hours apart.

It is a two-part study where Part 1 will enroll a small cohort of participants and will be used as a pilot study. The data obtained from Part 1 will be assessed by an internal AstraZeneca advisory board, and suggested changes may be made to Part 2 of the study.

The following is the sequence of study visits:

(i) Visit 1 (V1) screening (ii) Visit 2 (V2) 10 to 14 days after Visit 1 assessments; 1st dual challenge and treatment visit (iii) Visit 3 (V3) 10 to 14 days after Visit 2; 2nd dual challenge and treatment visit

At Visit 1, all participants will be subjected to a single mannitol challenge to establish a positive response (defined as a ≥15% decrease in forced expiratory volume in the first second [FEV1] from the 0 mg mannitol FEV1 value) and will receive 4 puffs of open-label PT007. At Visit 2, participants will be randomized to one of 2 treatment sequences, A/B or B/A, where treatments A and B are defined as:

(i) Treatment A = PT027 (ii) Treatment B = PT007

For treatment sequence A/B, participants will receive repeated inhalations of PT027 at Visit 2 followed by repeated inhalations of PT007 in Visit 3 .

For treatment sequence B/A, participants will receive repeated inhalations of PT007 at Visit 2 followed by repeated inhalations of PT027 in Visit 3.

Participants will have a Follow-up Telephone call 7 days after Visit 3/after Early discontinuation (ED).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 105
• Est. completion date: November 5, 2024
• Est. primary completion date: November 5, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

• Participants who have been diagnosed with asthma > 6 months before Visit 1 by a physician.

• Participants must have been prescribed and using as-needed SABA as only asthma treatment for at least 4 weeks before screening visit.

• Participants should have pre-bronchodilator FEV1 = 1.5 L and FEV1 = 60% to < 90% predicted normal at Visit 1.

• Participants should have a positive response to mannitol challenge performed at Visit 1 (a decrease in FEV1 by at least 15% [PD15] at = 635 mg).

• Participants should return to within 10% of baseline FEV1 (= 90% of baseline FEV1), within 1 hour after positive mannitol challenge and 4 inhalations of PT007, performed at Visit 1.

• Participants should be able to adhere to study procedures in the judgment of the Investigator.

• Male or female.

• Women of childbearing potential must have a negative urine pregnancy test at each study visit.

• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.

• Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of samples for optional genetic research that supports Genomic Initiative.

Exclusion Criteria:

• Any evidence of clinically significant lung disease other than asthma.

• If the participant has had any face-to-face unscheduled or urgent visit for asthma worsening within the last 4 weeks.

• Any significant disease or disorder, or evidence of drug/substance abuse which in the Investigator's opinion would pose a risk to participant safety, interfere with the conduct of study, have an impact on the study results, or make it undesirable for the participant to participate in the study.

• If participants have used Inhaled corticosteroids (ICS) within 1 month prior to enrolment.

• If they have used immunosuppressive medication (including but not limited to methotrexate, troleandomycin, cyclosporine, azathioprine, systemic corticosteroids including regular treatment with oral corticosteroids or intramuscular long-acting depot corticosteroids, or any experimental anti-inflammatory therapy) within 3 months prior to enrolment (Visit 1) or plan on starting immunosuppressive medications during the study.

• If they have used allergen-specific immunotherapy (desensitization) within 3 months prior to enrolment.

• If they have used systemic corticosteroids (including oral and injected) within 3 months prior to enrolment.

• If they have received any marketed or investigational biologic within 4 months or 5 half-lives prior to enrolment (whichever is longer) or received any investigational nonbiologic agent within 30 days or 5 half-lives prior to enrolment (whichever is longer).

• Participants with a known hypersensitivity to beta2-agonists, ICS, mannitol, or any of the excipients of the product.

• Any clinically significant abnormal findings in physical examination, vital signs, ECG (eg, participants with QTcF > 500 ms), hematology, clinical chemistry, or urinalysis, which in the opinion of the Investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete entire duration of the study.

• If they are current smokers or participants with smoking history = 10 pack years including the use of vaping products, such as electronic cigarettes, and water pipes. If they are former smokers with a smoking history of <10 pack years, including former vaping or water pipe users, smoking must have stopped for at least 6 months prior to Visit 1 to be eligible.

• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and its affiliates and/or staff at the study site and their immediate relative(s)).

• Judgment by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

• Breast feeding, pregnancy or intention to become pregnant during the course of the study.

• Previous randomization in the present study.

Related Conditions & MeSH terms

• Airway Obstruction
• Asthma

Intervention

Combination Product:
• PT027
When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.
• PT007
When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.

Locations

Country	Name	City	State
United States	Research Site	Columbia	Maryland
United States	Research Site	Columbia	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from mannitol baseline Forced expiratory volume in the first second (FEV1) Area under the curve (AUC [0-60 min]) post-mannitol challenge 1	The efficacy of repeated dosing of PT027 relative to PT007, on post-dose lung function, when used by participants with asthma on SABA as-needed treatment only who are experiencing acute airway obstruction induced by mannitol challenges will be assessed.	Up to 60 minutes post mannitol challenge 1
Secondary	Change from mannitol baseline in FEV1 AUC (0-15 min) post-mannitol challenge 1	The efficacy of PT027 after a single dose compared with PT007 in reversal of acute airway obstruction, when used by participants with asthma on SABA as-needed treatment only who are experiencing acute airway obstruction induced by mannitol challenges will be assessed.	Up to 15 minutes post mannitol challenge 1
Secondary	Change from mannitol baseline in FEV1 at 8 hours post-mannitol challenge 1	The efficacy of PT027 compared with PT007 in the sustainability of effect of reversal of acute airway obstruction post-mannitol challenge 1 in participants with asthma on SABA as needed treatment only who are experiencing acute airway obstruction induced by mannitol challenges will be assessed.	At 8 hours (480 minutes) post mannitol challenge 1
Secondary	Time to return to baseline (-30 min) FEV1 post-mannitol challenge 2, pre-final dose of rescue/reliever	The efficacy of a single dose of PT027 compared with PT007 on post-dose speed of recovery of lung function following a recurring trigger of acute airway obstruction induced by mannitol challenges in participants with asthma on SABA as needed treatment only will be assessed.	Up to 60 minutes post-mannitol challenge 2
Secondary	Peak fall in FEV1 from baseline (-30 min) FEV1 to post-mannitol challenge 2, pre-final dose of rescue/reliever	The protective efficacy of prior repetitive doses of PT027 compared with PT007 on lung function fall in response to a recurring trigger of acute airway obstruction induced by mannitol challenges in participants with asthma on SABA as-needed treatment only will be assessed.	At approximately 490 minutes post mannitol challenge 1
Secondary	Peak fall in FEV1 from 8 hours to post-mannitol challenge 2, pre-final dose of rescue/reliever	The protective efficacy of prior repetitive doses of PT027 compared with PT007 on lung function fall in response to a recurring trigger of acute airway obstruction in participants with asthma on SABA as-needed treatment only will be assessed.	To post-mannitol challenge 2 at approximately 490 minutes
Secondary	Number of participants with Adverse Events (AEs)	The safety and tolerability of repeated dosing of PT027 as compared to PT007 in participants with asthma on SABA as-needed treatment only will be assessed.	From Screening Visit (approximately 5 hours) until the Follow up telephone call (7 days after the last treatment visit)